According to people familiar with the matter, SK Capital Partners is nearing a deal to acquire Swiss drug distributor Swixx Biopharma, with an announcement possible as soon as Monday, Bloomberg reports.
The transaction could value Swixx at around €1.5 billion, with financing secured from alternative asset manager Ares.
SK Capital emerged as the preferred buyer after competing with other bidders, including DKSH Holding and investment firm Lone Star.
Swixx, owned by HBM Healthcare Investments and its managers, supports pharmaceutical companies distributing drugs in smaller markets with varying labelling and packaging rules.
The Baar-based company operates in 45 countries and reported more than €900 million in sales in 2024.
More Information
